Abstract: A novel anti-IL13 receptor ?1 antibody having an activity of inhibiting a cell response by IL13, in particular, having an activity of inhibiting the cell response by IL13 but not inhibiting the cell response by IL4, a characteristic amino acid sequence in a variable region thereof, and a method of detecting IL13 receptor ?1 in a sample using the same are provided.

Abstract: The present invention provides a method for qualitative determination of low molecular weight soluble CD14 proteins separately. The present invention also provides antibodies specific to high molecular weight soluble CD14 proteins. Further, the present invention provides a measurement method for specifically determining the quality or quantity of high molecular weight soluble CD14 proteins using the antibodies with high sensitivity, simplicity and specificity.

Abstract: The present invention provides an anti-CD14 antibody and fragments thereof that have a function of inhibiting the binding between CD14 and Toll Like Receptor (TLR). And also hybridomas producing the antibody or fragments thereof, peptides, method of preparing antibodies, CD14 mutant polypeptide, method of screening medicaments for treating sepsis and pharmaceutical compositions for sepsis were provided.

Abstract: The present invention provides an antibody which specifically recognizes an epitope containing a part of a domain based on a finding that the domain ranging from the 269- to 315-positions of human CD14 represented by SEQ ID NO:1 is a site capable of interacting with another protein, an antibodies provided. This antibody can inhibit the interaction between human CD14 and another protein and thus suppress cell activation. And also, the present invention provides hybridomas producing the above antibody or its fragment; a peptide containing the amino acids in the domain as specified above; a method of constructing an antibody with the use of this peptide as an immunogen; and a method of screening a medicament for sepsis involving the step of bringing a test substance into contact with CD14 and TLR.

Abstract: A gene of a novel cellular adhesion molecule participating in the regulation of immune functions and a protein, and a method of efficiently evaluating an activity regulator for this protein are provided.

Abstract: The purpose of the present invention is to provide a novel protein involved in adhesion and fusion between myoblasts in the course of the formation of byotube. The present invention relates to Meltrins, which a membrane protein having fusion, adhesion and aggregation activity of cells, especially myoblast; and to polypeptides of their domains, DNAs encoding them, antisense RNA for these DNAs, various antibodies to Meltrins and the polypeptides of their domains, expression vectors containing these DNAs, and transformants by these vectors; as well as to the process for producing Meltrins and the polypeptides of their domains using those transformants and medical compositions comprising Meltrins or antagonist against them as an effective ingredient.

Abstract: An anti-Fas ligand antibody capable of suppressing Fas ligand-induced apoptosis to a high degree, especially humanized antibodies having less antigenecity to human, and a method for assaying the Fas ligand in human body fluid utilizing such an antibody.Measurement of the Fas ligand in human body fluid would be useful for elucidation of hepatitis B, hepatitis C, HIV infections and the like, and for prediction and diagnosis of pathological conditions associated with such diseases.

Abstract: An agent for preventing or treating AIDS which contains as its effective component an anti-Fas ligand antibody, and the method for preventing and treating AIDS by using such drug.

Abstract: A method for the measurement of adenyl group-containing substances which comprises deriving a chemiluminescent substance by allowing a compound to react with adenyl group in a substance to be measured, and qualitatively or quantitatively measuring the substance to be measured using a luminescent intensity obtained from the chemiluminescent substance as a marker.

Abstract: The invention provides an assay by which detection and/or quantitation of adenyl group-containing substances can be performed simply, with high sensitivity and high signal-to-noise ratio. In particular, the method provides an assay in which the chemiluminescence of a chemiluminescent substance, made by reacting a glyoxal derivative with an adenyl group in the substance to be detected/quantitated in the presence of a heteropolyacid or a heteropolyacid salt, is measured.